We hypothesize that GP-based follow-up is as effective as specialist-based follow-up care in terms of (1) adherence to the prostate surveillance guideline regarding the timing and frequency of PSA measurements; (2) the time from a BCR to prostate cancer retreatment decision-making; (3) the management of treatment-related side effects, as experienced by patients; (4) health-related quality of life and prostate cancer-related anxiety; (5) continuity of care and; (6) costs-effectiveness. The gene discussed is KLK3; the disease is Anxiety.